订阅最新相关文献

A bispecific antibody is described comprising a first antigen binding arm that binds FRa receptor and a second antigen-binding arm that binds CD3, wherein: a) the first antigen-binding arm (A) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), A- VHCDR1, A-VHCDR2 and A- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 1, 2 and 3 respectively three light chain complementarity determining regions (CDRs), A- VLCDR1, A-VLCDR2 and A- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 4, 5 and 6 respectively b) the second antigen-binding arm (B) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), B- VHCDR1, B-VHCDR2 and B- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 7, 8 and 9 respectively three light chain complementarity determining regions (CDRs), B- VLCDR1, B-VLCDR2 and B- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 10, 11 and 12 respectively. Furthermore, the pharmaceutical composition comprising said bispecific antibody and its pharmaceutical use are described.

The present invention relates to a process for preparing the compound of Formula I in the form of a base or a salt thereof, and its use as an intermediate for the preparation of calcitonin gene- related peptide (CGRP) receptor antagonist active pharmaceutical ingredients, in particular zavegepant, where the compound of Formula I is the following: (I)

The present invention generally relates to the field of nanocellulose-based nanocomposites. In particular, the present invention relates to adducts between a nanocellulose, in particular a nanofibrillated cellulose, and a peptide of sequence DFNKF, wherein one or both of the phenylalanine residues can optionally be halogenated on the aromatic ring. The present invention further relates to a process for the preparation of said adducts, films based on said adducts and the process for obtaining them, and uses of said adducts and films.

The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain covalently linked to a nonglycolsylated Fc domain, and uses thereof.

A bispecific antibody is described comprising a first antigen binding arm that binds FRa receptor and a second antigen-binding arm that binds CD3, wherein: a) the first antigen-binding arm (A) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), A- VHCDR1, A-VHCDR2 and A- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 1, 2 and 3 respectively three light chain complementarity determining regions (CDRs), A- VLCDR1, A-VLCDR2 and A- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 4, 5 and 6 respectively b) the second antigen-binding arm (B) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), B- VHCDR1, B-VHCDR2 and B- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 7, 8 and 9 respectively three light chain complementarity determining regions (CDRs), B- VLCDR1, B-VLCDR2 and B- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 10, 11 and 12 respectively. Furthermore, the pharmaceutical composition comprising said bispecific antibody and its pharmaceutical use are described.

The present invention relates to a process for preparing (15α,16α,17β)-estra-1,3,5(10)-triene- 3,15,16,17-tetrol monohydrate, also known as Estetrol monohydrate, having formula (I).

本发明涉及一种6‑三氟甲基靛红的合成方法，包括以下步骤：4‑氯‑3‑硝基三氟甲苯与丙二酸二乙酯在碱和第一溶剂的体系中，经芳香亲核取代反应，生成中间体Ⅰ（2‑[2‑硝基‑4‑(三氟甲基)苯基]丙二酸二乙酯）；中间体Ⅰ在还原剂以及第二溶剂的体系中，经硝基还原与分子内环化反应生成中间体Ⅱ（6‑三氟甲基氧化吲哚）；6‑三氟甲基氧化吲哚在催化剂、氧化剂和第三溶剂的体系中，经氧化芳构化反应生成6‑三氟甲基靛红。本发明通过三步反应，逐步构建靛红骨架，同时确保三氟甲基稳定存在于芳环的6位，得到目标产物6‑三氟甲基靛红，实现高收率与高选择性；本发明方法操作简便，适用于工业生产。